Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
AbstractObjectivesWe will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill.Trial designThis is a phase 3, single-center, randomized, open-label, controlled trial with a parallel-group design carried out at Shahid Mohammadi Hospital, Bandar Abbas, Iran.ParticipantsAll patients with age ≥ 20 years admitted at the Severe Acute Respiratory Syndrome Departments of the Shahid Mohammadi Hospital, Bandar Abbas, Iran, will be screened for the following criteria.Inclusion criteria:Confirme...
Source: Trials - October 27, 2020 Category: Research Source Type: clinical trials
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial
This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences.Intervention and ComparatorCOVID- 19 confirmed patients (using the RT-PCR test or CT scan) will be randomly assigned to one of two groups. The intervention group (Arms1) will be treated with lopinavir / ritonavir (Kaletra) + high dose Interferon- β 1a (Recigen) and the control group will be treated with lopinavir / ritonavir (Kaletra) + low dose Interferon-β 1a (Recigen) (the base therapeutic regimen). Both groups will receive standard care consisting of the necessary oxygen support, non-invasive, or invasive mecha...
Source: Trials - October 26, 2020 Category: Research Source Type: clinical trials
NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins
August 6, 2020 -- A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in patients with coronavirus disease 2019... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 6, 2020 Category: Pharmaceuticals Source Type: clinical trials
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial
This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services.Intervention and comparatorCOVID-19 confirmed patients will be randomly assigned to one of three groups, with 20 patients in each. The first group (Arm 1) will receive Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon- β 1a (Recigen), the second group (Arm 2) will be administered Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon-β 1b (Ziferon), and the control group (Arm 3) will be treated by Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra).Main outcomesTime t...
Source: Trials - June 2, 2020 Category: Research Source Type: clinical trials
Interferon Beta 1a in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
Condition: COVID-19 Interventions: Drug: Interferon Beta-1A; Drug: Lopinavir / Ritonavir; Drug: Single Dose of Hydroxychloroquine Sponsor: Shahid Beheshti University of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2020 Category: Research Source Type: clinical trials
Interferon Beta 1a in Hospitalized COVID-19 Patients
Condition: COVID-19 Interventions: Drug: Interferon Beta-1A; Drug: Lopinavir / Ritonavir; Drug: Single Dose of Hydroxychloroquine Sponsor: Shahid Beheshti University of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2020 Category: Research Source Type: clinical trials
